About

Richard Vellacott is Non-executive Chairman at BiologIC Technologies. He was previously Chief Financial Officer of Horizon Discovery Group for seven years, leading one of the most successful ever life sciences IPOs on AIM – raising £68.6 million in a heavily oversubscribed IPO at the top of its valuation range – followed by two major US acquisitions within six months. He has a first-class degree in Biological Sciences from Durham University (UK) and is a qualified chartered accountant, advising numerous companies from lab bench to global pharma. Mr Vellacott has also been Vice-President, Finance at FTSE 250 company CSR. Before that, he was a director in Deloitte’s life sciences practice, working with leading life science companies such as AstraZeneca, Vectura, Cambridge Antibody Technology and Abcam. He specialised in capital market transactions including numerous IPOs, mergers and acquisitions, and fundraisings.